Gennaro is a physician-neuroscientist and pharma medical director with 15+ years of translational research in academia and early clinical development. He is leading the early clinical development of Prasinezumab for Parkinson’s disease at Roche Pharma Research & Early Development (pRED). He served as PSAB Chair of the PPMI (2020-2021) and is currently serving as the Industry co-director of Critical Path for Parkinson’s disease, and Honorary Clinical Associate Professor at University of Exeter Medical School, London. He obtained a Doctor of Medicine (MD) at University of Naples Federico II, Master in Epidemiology (MSc) at University of Milan, Doctor of Philosophy (PhD) in Clinical Neuroscience at King’s College London, and postdoctoral training in PET imaging with focus on genetics, preclinical and prodromal Parkinson’s disease at Imperial College London. He also completed fellowships in movement disorders/neuroimaging at Mount Sinai Medical Center in New York and Cedars Sinai Medical Center in Los Angeles.

Clinician scientist at Department of Neurology, LMU Munich, with focus on 4R tauopathies

Sebastian Palmqvist is a senior consultant neurologist at the Memory Clinic of Skåne University Hospital in Malmö, where he sees patients two days a week, and an associate professor and senior lecturer of neurology at Lund University in Sweden. During the last 15 years, dr Palmqvist’s research has been focused on cognitive assessments and biomarkers in Alzheimer’s disease for improving clinical diagnostics. He has published more than 100 articles including first/last author publications in journals such as JAMA, Nature Medicine, Brain, JAMA Neurology, Alzheimer’s & Dementia, and EMBO Molecular Medicine. He currently heads the BioFINDER-Primary Care study, which focuses on examining and implementing blood-based biomarkers and novel cognitive tests in primary care for improving the work-up of Alzheimer’s disease and cognitive impairment. Dr Palmqvist is active as a clinician, researcher, teacher and supervisor as well as co-chair of the AAIC Scientific Program Committee and PI of the Strategic Research Area MultiPark at Lund University where he is also part of the steering committee. Dr Palmqvist’s research is supported by the NIA, Alzheimer’s Association, Swedish Research Council, the Swedish Brain Foundation, The Swedish Alzheimer Association, and MultiPark at Lund University, among others. Previous awards for his work include the Inga Sandeborgs award by the Swedish Medical Society, Bundy Academy Award – Major prize at Lund University, Her Majesty Queen Silva’s Award to a young Alzheimer researcher, the Swedish Alzheimer Association’s Award for best publication of the year (Palmqvist et al., JAMA 2020), AD/PD Junior Faculty Award, among others, and he was in 2022 and 2023 appointed “Highly cited researcher” by Clarivate demonstrated by the production of multiple highly-cited papers that rank in the top 1% by citations in the Web of Science the last decade.

Joseph M Palumbo, MD, LFAPA, MACPsych, is Chief Medical Officer of BioVie Inc. Prior to his appointment at BioVie, Dr. Palumbo was Chief Medical Officer at Zynerba. He previously held senior worldwide governance roles at Mitsubishi Tanabe Pharma in both the United States and Japan, with earlier leadership experiences in European and American pharma. Dr. Palumbo holds a BA from the University of Pennsylvania and a Doctor of Medicine from the George Washington University School of Medicine. He was a Biological Sciences Training Program Fellow of the National Institutes of Health and Chief Resident for the Abraham Ribicoff Clinical Neuroscience Research Unit at Yale University. He has held academic appointments at Yale Medical School, Cornell, and the University of Pennsylvania. He is a member of the Dean’s Council of Advisors at the George Washington University.

Indrashil University, Kadi, Rajpur

Dominik Paquet is a Professor at the Institute for Stroke and Dementia Research (ISD) of the University Hospital of LMU Munich, Germany. He received his PhD for work with Christian Haass at LMU Munich and performed postdoctoral work as a NYSCF Druckenmiller Fellow with Marc Tessier-Lavigne at Rockefeller University, where he developed efficient technologies to gene-edit iPSCs with CRISPR and differentiate them into human brain cells. In 2017 Dr. Paquet established the PaquetLab (www.isd-research.de/PaquetLab) at ISD and currently serves as Professor of Neurobiology and core member of Synergy (www.synergy-munich.de), a leading Research Cluster of the Excellence Initiative of the German research funding organization. Using his broad background in neurodegenerative disease research, with specific training and expertise in molecular, stem cell and neurobiology, he leads an interdisciplinary team of neurobiologists, biochemists, and stem cell biologists. The PaquetLab uses cutting-edge technologies such as CRISPR genome editing, iPSC differentiation and human 3D tissue engineering to elucidate the molecular function of the human brain and the mechanisms leading to neurodegenerative and neurovascular diseases.